Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,680,131
  • Shares Outstanding, K 213,047
  • Annual Sales, $ 63,720 K
  • Annual Income, $ -193,510 K
  • EBIT $ -251 M
  • EBITDA $ -247 M
  • 60-Month Beta 0.96
  • Price/Sales 41.56
  • Price/Cash Flow N/A
  • Price/Book 8.38

Options Overview Details

View History
  • Implied Volatility 91.78% (+0.51%)
  • Historical Volatility 44.29%
  • IV Percentile 86%
  • IV Rank 41.62%
  • IV High 155.99% on 04/08/25
  • IV Low 46.01% on 08/22/25
  • Expected Move (DTE 13) 1.15 (9.12%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 3,508
  • Volume Avg (30-Day) 1,534
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 76,615
  • Open Int (30-Day) 75,974
  • Expected Range 11.43 to 13.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.30 +22.14%
on 11/07/25
13.00 -3.23%
on 12/04/25
+1.77 (+16.37%)
since 11/05/25
3-Month
10.30 +22.14%
on 11/07/25
13.65 -7.84%
on 09/08/25
-1.02 (-7.50%)
since 09/05/25
52-Week
5.78 +117.46%
on 03/04/25
13.85 -9.17%
on 09/05/25
+3.40 (+37.04%)
since 12/05/24

Most Recent Stories

More News
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global,...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ to Participate in November and December Investor Conferences

BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 12.58 (+1.21%)
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 ...

OCUL : 12.58 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 13.07
2nd Resistance Point 12.88
1st Resistance Point 12.73
Last Price 12.58
1st Support Level 12.39
2nd Support Level 12.20
3rd Support Level 12.05

See More

52-Week High 13.85
Last Price 12.58
Fibonacci 61.8% 10.77
Fibonacci 50% 9.82
Fibonacci 38.2% 8.87
52-Week Low 5.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar